Last reviewed · How we verify
rifampin IV
Rifampin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.
Rifampin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis. Used for Tuberculosis (pulmonary and extrapulmonary), Mycobacterium avium complex (MAC) infection, Leprosy.
At a glance
| Generic name | rifampin IV |
|---|---|
| Also known as | RIFADIN™ |
| Sponsor | University of California, San Francisco |
| Drug class | Rifamycin antibiotic |
| Target | Bacterial RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Rifampin binds to the bacterial RNA polymerase enzyme and inhibits RNA synthesis by blocking the path of elongating RNA transcripts. This mechanism is selective for bacterial RNA polymerase and does not significantly affect eukaryotic RNA polymerases, making it effective as an antibiotic. The drug is bactericidal and has broad-spectrum activity against many gram-positive and gram-negative bacteria, as well as mycobacteria.
Approved indications
- Tuberculosis (pulmonary and extrapulmonary)
- Mycobacterium avium complex (MAC) infection
- Leprosy
- Endocarditis (as adjunctive therapy)
- Atypical mycobacterial infections
Common side effects
- Hepatotoxicity
- Discoloration of body fluids (orange-red)
- Drug interactions (enzyme induction)
- Rash
- Gastrointestinal disturbance
- Thrombocytopenia
Key clinical trials
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus (PHASE3)
- Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2) (PHASE3)
- STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis (PHASE3)
- Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia (PHASE2, PHASE3)
- Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? (PHASE4)
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rifampin IV CI brief — competitive landscape report
- rifampin IV updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI